- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02379390
Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide (PRIMCAB)
Phase II, Randomized, Open-label, Multicenter Study in Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Who Have PRIMary Resistance to Abiraterone Acetate or Enzalutamide Treatment Comparing the Anti-tumor Effect of CABazitaxel to Alternative Androgen Receptors (AR) Targeted Therapy
Primary Objective:
To demonstrate the superiority in term of radiographic Progression-Free Survival (rPFS) of cabazitaxel at at 25 milligram per meter square (mg/m^2) plus prednisone (Arm A) versus either enzalutamide at 160 milligram (mg) once daily or abiraterone acetate at 1000 mg once daily plus prednisone (Arm B) in chemotherapy-naïve participants with metastatic Castration-Resistant Prostate Cancer (mCRPC) who have disease progression while receiving androgen receptor (AR) targeted therapy (abiraterone plus prednisone or enzalutamide) within 12 months of treatment initiation (≤12 months).
Secondary Objective:
- To compare efficacy for:
- Prostate-specific antigen (PSA) response rate and Time to PSA progression (TTPP).
- Progression Free Survival (PFS).
- Overall Survival (OS).
- Tumor response rate in participants with measurable disease (RECIST 1.1)
- Pain response and time to pain progression.
- Symptomatic skeletal events (SSE) rate and time to occurrence of any SSE.
- To analyze messenger ribonucleic acids (mRNAs) including androgen-receptor splice variant 7 messenger RNA (AR-V7) as a biomarker in Circulating Tumor Cells (CTCs).
- To evaluate safety in the 2 treatment arms.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Edmonton, Canada, T6G 1Z2
- Investigational Site Number 124003
-
Greenfield Park, Canada, J4V2H1
- Investigational Site Number 124010
-
Hamilton, Canada, L8V 5C2
- Investigational Site Number 124005
-
London, Canada, N6A 4L6
- Investigational Site Number 124004
-
Montreal, Canada, H2L 4M1
- Investigational Site Number 124002
-
Montreal, Canada, H2W1S6
- Investigational Site Number 124006
-
Ottawa, Canada, K1H8L6
- Investigational Site Number 124007
-
Quebec, Canada, G1R 2J6
- Investigational Site Number 124009
-
Saskatoon, Canada, S7N4H4
- Investigational Site Number 124008
-
Vancouver, Canada, N5Z4E6
- Investigational Site Number 124001
-
-
-
-
Alabama
-
Muscle Shoals, Alabama, Stati Uniti, 35661
- Investigational Site Number 840030
-
-
Alaska
-
Anchorage, Alaska, Stati Uniti, 99508
- Investigational Site Number 840024
-
-
California
-
Anaheim, California, Stati Uniti, 92801
- Investigational Site Number 840028
-
Sacramento, California, Stati Uniti, 95817
- Investigational Site Number 840004
-
-
Florida
-
Boca Raton, Florida, Stati Uniti, 33486
- Investigational Site Number 840002
-
Lakeland, Florida, Stati Uniti, 33805
- Investigational Site Number 840027
-
Port Saint Lucie, Florida, Stati Uniti, 34952
- Investigational Site Number 840006
-
-
Illinois
-
Ottawa, Illinois, Stati Uniti, 61350
- Investigational Site Number 840015
-
-
Louisiana
-
Covington, Louisiana, Stati Uniti, 70433
- Investigational Site Number 840001
-
Metairie, Louisiana, Stati Uniti, 70006
- Investigational Site Number 840017
-
-
Maryland
-
Rockville, Maryland, Stati Uniti, 20850
- Investigational Site Number 840012
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68198
- Investigational Site Number 840026
-
-
Ohio
-
Canton, Ohio, Stati Uniti, 44718
- Investigational Site Number 840022
-
-
South Carolina
-
Myrtle Beach, South Carolina, Stati Uniti, 29572
- Investigational Site Number 840016
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria:
- Diagnosis of histologically or cytologically confirmed prostate adenocarcinoma.
- Metastatic disease.
- Progressive disease (PD) while receiving AR targeted therapy with abiraterone acetate or enzalutamide within 12 months of treatment initiation (≤12 months) by at least one of the following:
- Progression in measurable disease Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
- Appearance of 2 or more new bone lesions according to Prostate Cancer Working Group 2 (PCWG2).
- Rising PSA defined (PCWG2) as at least two consecutive rises in PSA to be documented over a reference value (measure 1) taken at least one week apart.
- A PSA value of at least 2 nanogram/milliliter (ng/mL) is required at study entry.
- Effective castration (serum testosterone levels ≤0.5 ng/mL).
- Prior AR targeted therapy (abiraterone acetate or enzalutamide) must be stopped at least 2 weeks before study treatment.
- Signed written informed consent.
Exclusion criteria:
- Prior chemotherapy for prostate cancer, except estramustine and except adjuvant/neoadjuvant treatment completed >3 years ago. No further anti-cancer therapy after the previous AR targeted therapy and before inclusion. Prior docetaxel in hormone sensitive setting is allowed if completed >1 year before randomization. Prior immunotherapy is allowed.
- Less than 28 days elapsed from prior treatment with immunotherapy, radiotherapy, or surgery to the time of randomization.
- Adverse events (excluding alopecia and those listed in the specific exclusion criteria) from any prior anticancer therapy of grade >1(National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.0) at the time of randomization.
- Eastern Cooperative Oncology Group (ECOG) performance status >1.
- History of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease.
- Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which treatment has been completed ≥5 years ago and from which the patient has been disease-free for ≥5 years.
- Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.
- Acquired immunodeficiency syndrome (AIDS)-related illnesses or known Human immunodeficiency virus (HIV) disease requiring antiretroviral treatment.
- Any severe acute or chronic medical condition including uncontrolled diabetes mellitus, severe renal impairment, history of cardiovascular disease (uncontrolled hypertension, arterial thrombotic events in the past 6 months, congestive heart failure, severe or unstable angina pectoris, recent myocardial infraction within last 6 months or uncontrolled cardiac arrhythmia), which could impair the ability of the patient to participate to the study or interfere with interpretation of study results, or patient unable to comply with the study procedures.
- Participants with reproductive potential who do not agree to use accepted and effective method of contraception during the study treatment period and up to 6 months after the last administered dose. The definition of "effective method of contraception" will be based on the Investigator's judgment.
- Known allergies, hypersensitivity or intolerance to prednisone or excipients of abiraterone acetate or enzalutamide. History of hypersensitivity to docetaxel or polysorbate 80.
- Known history of mineralocorticoid excess or deficiency (not applicable to participants who have already been treated with abiraterone acetate in first line before inclusion).
- History of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain arteriovenous malformation or the use of concomitant medications that may lower the seizure threshold (not applicable to participants who have already been treated with enzalutamide in first line before inclusion).
- Unable to swallow a whole tablet or capsule.
- Inadequate organ and bone marrow function as evidenced by:
- Hemoglobin <10.0 g/dL.
- Absolute neutrophil count <1.5 x 10^9/L.
- Platelet count <100 x 10^9/L.
- Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) >1.5 x Upper limit of normal (ULN).
- Total bilirubin >1.0 x ULN.
- Potassium <3.5 mmol/L.
- Serum albumin <3.0 g/dL.
- Child-Pugh Class B and C.
- Contraindications to the use of corticosteroid treatment.
- Symptomatic peripheral neuropathy grade ≥2 NCI CTCAE v4.0.
- Concomitant vaccination with yellow fever vaccine.
The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Cabazitaxel
Participants received Cabazitaxel 25 mg/m^2, intravenously for 1 hour along with prednisone 10 mg orally on Day 1 of every treatment cycle (each cycle was of 3 weeks) until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
|
Altri nomi:
|
Comparatore attivo: Abiraterone acetate or Enzalutamide
Participants received abiraterone acetate 1000 mg (4 tablets of 250 mg), orally once daily along with prednisone 5 mg, orally twice daily from Day 1 to 21 in each treatment cycle (each cycle was of 3 weeks) or enzalutamide 160 mg, orally, until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
|
Altri nomi:
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Radiographic Progression-Free Survival (rPFS)
Lasso di tempo: Baseline until tumor progression or bone lesion progression or death due to any cause (maximum duration: 1059 days)
|
rPFS was defined as the time from randomization to the first occurrence of radiological tumor progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or progression of bone lesions using prostate cancer working group 2 (PCWG2) criteria or death due to any cause.
|
Baseline until tumor progression or bone lesion progression or death due to any cause (maximum duration: 1059 days)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Participants With Prostate Specific Antigen (PSA) Response
Lasso di tempo: Baseline up to PSA progression or death due to any cause (maximum duration: 1059 days)
|
PSA response was defined as decline of serum PSA from baseline by >= 50 percent (%).
|
Baseline up to PSA progression or death due to any cause (maximum duration: 1059 days)
|
Progression-free Survival (PFS)
Lasso di tempo: Baseline upto progression or death due to any cause (maximum duration: 1059 days)
|
PFS: time interval between date of randomization to first documentation of tumor progression as per RECIST 1.1.
|
Baseline upto progression or death due to any cause (maximum duration: 1059 days)
|
Overall Survival
Lasso di tempo: Baseline until death or study cut-off date, whichever was earlier (maximum duration: 1059 days)
|
Overall Survival was defined as the time interval from the date of randomization to the date of death due to any cause.
|
Baseline until death or study cut-off date, whichever was earlier (maximum duration: 1059 days)
|
Time to PSA Progression
Lasso di tempo: Baseline up to PSA progression or death due to any cause (maximum duration: 1059 days)
|
Time to PSA progression was defined as the time interval between the date of randomization and the date of first documented PSA progression as per PCWG2 criteria.
|
Baseline up to PSA progression or death due to any cause (maximum duration: 1059 days)
|
Number of Participants Achieving Tumor Response
Lasso di tempo: Baseline up to disease progression or death due to any cause (maximum duration: 1059 days)
|
Tumor response was defined as either a partial response (PR) or complete response (CR) according to the RECIST 1.1.
|
Baseline up to disease progression or death due to any cause (maximum duration: 1059 days)
|
Duration of Tumor Response
Lasso di tempo: Baseline up to disease progression or death due to any cause (maximum duration: 1059 days)
|
Duration of tumor response was defined as the time between the first evaluation at which the tumor response criteria were met and the first documentation of tumor progression.
|
Baseline up to disease progression or death due to any cause (maximum duration: 1059 days)
|
Pain Response Using Brief Pain Inventory-Short Form (BPI-SF) for Pain Intensity Score
Lasso di tempo: Baseline until the end of study (maximum duration: 1059 days)
|
Pain response was analyzed using the brief pain inventory-short form (BPI-SF).
|
Baseline until the end of study (maximum duration: 1059 days)
|
Time to Pain Progression
Lasso di tempo: Baseline until disease progression, start of another anticancer therapy or study cut off, whichever came first (maximum duration: 1059 days)
|
Time to pain progression was defined as the time interval between the date of randomization and the date of the first documented pain progression.
|
Baseline until disease progression, start of another anticancer therapy or study cut off, whichever came first (maximum duration: 1059 days)
|
Percentage of Participants With Symptomatic Skeletal Event (SSE)
Lasso di tempo: Baseline until the end of study (maximum duration: 1059 days)
|
SSE was the occurrence of a new symptomatic pathological fracture, or the use of external beam radiation to relieve bone pain, or the occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention.
|
Baseline until the end of study (maximum duration: 1059 days)
|
Time to Occurrence of Any Symptomatic Skeletal Events (SSE)
Lasso di tempo: Baseline up to occurrence of the first event defining a SSE (maximum duration: 1059 days)
|
Time to SSE was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SSE, whichever is earlier.
|
Baseline up to occurrence of the first event defining a SSE (maximum duration: 1059 days)
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie genitali, maschio
- Malattie della prostata
- Neoplasie prostatiche
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antinfiammatori
- Agenti antineoplastici
- Glucocorticoidi
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Agenti antineoplastici, ormonali
- Inibitori dell'enzima del citocromo P-450
- Antagonisti ormonali
- Inibitori della sintesi di steroidi
- Prednisone
- Acetato di Abiraterone
Altri numeri di identificazione dello studio
- LPS14022
- U1111-1160-6008 (Altro identificatore: UTN)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro alla prostata metastatico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Attivo, non reclutanteStadio III Adenocarcinoma della prostata AJCC v7 | Stadio II Adenocarcinoma prostatico AJCC v7 | Fase I Adenocarcinoma della prostata American Joint Committee on Cancer (AJCC) v7Stati Uniti
Prove cliniche su Prednisone
-
Tel-Aviv Sourasky Medical CenterSconosciutoMalattia da graffio di gatto | Infezioni da bartonellaIsraele
-
Shanghai Children's Medical CenterNon ancora reclutamentoEmangioendotelioma kaposiforme (KHE) con fenomeno di Kasabach-Merritt (KMP)Cina
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationReclutamentoTosse post-infettivaSvizzera
-
Claudio GobbiEnte Ospedaliero Cantonale, Ticino, SwitzerlandTerminatoSclerosi multiplaSvizzera
-
Leiden University Medical CenterAttivo, non reclutanteCancro al seno | Cancro alla prostataOlanda
-
Sorlandet Hospital HFCompletato
-
University of HelsinkiUniversity of Turku; Oulu University Hospital; Kuopio University Hospital; Seinajoki... e altri collaboratoriSconosciuto
-
University of GiessenCompletatoLinfomi della zona marginale | Linfomi non Hodgkin | Linfomi follicolari | Immunocitomi | Linfomi linfocitariGermania
-
Amsterdam UMC, location VUmcCompletatoDiabete mellito | Diabete steroideo | Diabete indotto da glucocorticoidi | Funzione delle cellule betaOlanda
-
St. Jude Children's Research HospitalCompletatoLinfoma non Hodgkin | Leucemia linfoblastica acuta, cellule B matureStati Uniti